Expression of MMP-2, -7, -9, MT1-MMP and TIMP-1 and -2 has no prognostic relevance in patients with advanced epithelial ovarian cancer

Oncology Reports

Volumn 27, Issue 4, 2012, Pages 1049-1057

  Brun, Jean Luc ^a,b   Cortez, Annie ^a   Lesieur, Bénédicte ^a   Uzan, Serge ^a,c   Rouzier, Roman ^a,c   Daraï, Emile ^a,c  

^a HÔPITAL TENON   (France)

^b HÔPITAL PELLEGRIN   (France)

^c SORBONNE UNIVERSITÉ   (France)

Author keywords

Matrix metalloproteinase; Ovarian neoplasms; Prognosis

Indexed keywords

GELATINASE A; GELATINASE B; MATRILYSIN; MATRIX METALLOPROTEINASE 14; TISSUE INHIBITOR OF METALLOPROTEINASE 1; TISSUE INHIBITOR OF METALLOPROTEINASE 2;

ADULT; ADVANCED CANCER; AGED; ARTICLE; CANCER SURVIVAL; CONTROLLED STUDY; CYTOREDUCTIVE SURGERY; EPITHELIUM CELL; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; OVARY CANCER; PRIORITY JOURNAL; PROGNOSIS; PROTEIN ANALYSIS; PROTEIN EXPRESSION; PROTEIN FUNCTION; TISSUE MICROARRAY; TUMOR VOLUME;

ADULT; AGED; AGED, 80 AND OVER; CHEMOTHERAPY, ADJUVANT; CHI-SQUARE DISTRIBUTION; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; KAPLAN-MEIER ESTIMATE; MATRIX METALLOPROTEINASE 14; MATRIX METALLOPROTEINASE 2; MATRIX METALLOPROTEINASE 7; MATRIX METALLOPROTEINASE 9; MIDDLE AGED; NEOADJUVANT THERAPY; NEOPLASM GRADING; NEOPLASMS, GLANDULAR AND EPITHELIAL; OVARIAN NEOPLASMS; OVARIECTOMY; PARIS; PRINCIPAL COMPONENT ANALYSIS; RISK ASSESSMENT; RISK FACTORS; TIME FACTORS; TISSUE ARRAY ANALYSIS; TISSUE INHIBITOR OF METALLOPROTEINASE-1; TISSUE INHIBITOR OF METALLOPROTEINASE-2; TREATMENT OUTCOME; TUMOR MARKERS, BIOLOGICAL;

EID: 84856573452     PISSN: 1021335X     EISSN: 17912431     Source Type: Journal    
DOI: 10.3892/or.2011.1608     Document Type: Article

References (34)

1. Schröpfer A, Kammerer U, Kapp M, Dietl J, Feix S and Anacker J: Expression pattern of matrix metalloproteinases in human gynecological cancer cell lines. BMC Cancer 13: 553, 2010.
2. Wu X, Li H, Kang L, Wang W and Shan B: Activated matrix metalloproteinase-2: a potential marker of prognosis for epithelial ovarian cancer. Gynecol Oncol 84: 126-134, 2002. (Pubitemid 34056478)
3. Planagumà J, Liljeström M, Alameda F, et al: Matrix metalloproteinase- 2 and matrix metalloproteinase-9 codistribute with transcription factors RUNX1/AML1 and ETV5/ERM at the invasive front of endometrial and ovarian carcinoma. Hum Pathol 42: 57-67, 2011.
4. Wang FQ, So J, Reierstad S and Fishman DA: Matrilysin (MMP-7) promotes invasion of ovarian cancer cells by activation of progelatinase. Int J Cancer 114: 19-31, 2005. (Pubitemid 40194305)
5. Moss NM, Barbolina MV, Liu Y, Sun L, Munshi HG and Stack MS: Ovarian cancer cell detachment and multicellular aggregate formation are regulated by membrane type 1 matrix metalloproteinase: a potential role in I.p. metastatic dissemination. Cancer Res 69: 7121-7129, 2009.
6. Huang LW, Garrett AP, Bell DA, Welch WR, Berkowitz RS and Mok SC: Differential expression of matrix metalloproteinase- 9 and tissue inhibitor of metalloproteinase-1 protein and mRNA in epithelial ovarian tumors. Gynecol Oncol 77: 369-376, 2000. (Pubitemid 30368552)
7. Kim TJ, Rho SB, Choi YL, et al: High expression of tissue inhibitor of metalloproteinase-2 in serous ovarian carcinomas and the role of this expression in ovarian tumorigenesis. Hum Pathol 37: 906-913, 2006. (Pubitemid 43902953)
8. Davidson B, Goldberg I, Gotlieb WH, et al: High levels of MMP-2, MMP-9, MT1-MMP and TIMP-2 mRNA correlate with poor survival in ovarian carcinoma. Clin Exp Metastasis 17: 799-808, 1999.
9. Davidson B, Reich R, Berner A, et al: Ovarian carcinoma cells in serous effusions show altered MMP-2 and TIMP-2 mRNA levels. Eur J Cancer 37: 2040-2049, 2001. (Pubitemid 32938107)
10. Davidson B, Goldberg I, Gotlieb WH, Kopolovic J, Ben-Baruch G, Nesland JM and Reich R: The prognostic value of metalloproteinases and angiogenic factors in ovarian carcinoma. Mol Cell Endocrinol 187: 39-45, 2002. (Pubitemid 34436931)
11. Kamat AA, Fletcher M, Gruman LM, et al: The clinical relevance of stromal matrix metalloproteinase expression in ovarian cancer. Clin Cancer Res 12: 1707-1714, 2006.
12. Périgny M, Bairati I, Harvey I, et al: Role of immunohistochemical overexpression of matrix metalloproteinases MMP-2 and MMP-11 in the prognosis of death by ovarian cancer. Am J Clin Pathol 129: 226-231, 2008. (Pubitemid 352029312)
13. Rauvala M, Puistola U and Turpeenniemi-Hujanen T: Gelatinases and their tissue inhibitors in ovarian tumors; TIMP-1 is a predictive as well as a prognostic factor. Gynecol Oncol 99: 656-663, 2005. (Pubitemid 41686550)
14. Sillanpää SM, Anttila MA, Voutilainen KA, et al: Prognostic significance of matrix metalloproteinase-7 in epithelial ovarian cancer and its relation to β-catenin. Int J Cancer 119: 1792-1799, 2006. (Pubitemid 44356835)
15. Sillanpää S, Anttila M, Suhonen K, et al: Prognostic significance of extracellular matrix metalloproteinase inducer and matrix metalloproteinase 2 in epithelial ovarian cancer. Tumour Biol 28: 280-289, 2007. (Pubitemid 350165834)
16. Sillanpää S, Anttila M, Voutilainen K, et al: Prognostic significance of matrix metalloproteinase-9 (MMP-9) in epithelial ovarian cancer. Gynecol Oncol 104: 296-303, 2007. (Pubitemid 46135666)
17. Benedet JL, Bender H, Jones III H, Ngan HYS and Pecorelli S: FIGO staging classifications and clinical practice guidelines in the management of gynecologic cancers. FIGO Committee on Gynecologic Oncology. Int J Gynecol Obstet 70: 209-262, 2000.
18. Brun JL, Cortez A, Commo F, Uzan S, Rouzier R and Daraï E: Serous and mucinous ovarian tumors express different profiles of MMP-2, -7, -9, MT1-MMP, and TIMP-1 and -2. Int J Oncol 33: 1239-1246, 2008.
19. Skacel M, Skilton B, Pettay JD and Tubbs RR: Tissue microarrays: a powerful tool for high-throughput analysis of clinical specimen: a review of the method with validation data. Appl Immunohistochem Mol Morphol 10: 1-6, 2002. (Pubitemid 34178269)
20. Graesslin O, Cortez A, Fauvet R, Lorenzato M, Birembaut P and Darai E: Metalloproteinase-2, -7 and -9 and tissue inhibitor of metalloproteinase-1 and -2 expressions in normal, hyperplastic and neoplastic endometrium: a clinical-pathological correlation study. Ann Oncol 17: 637-645, 2006.
21. Budwit-Novotny DA, McCarty KS, Cox EB, et al: Immuno- histochemical analyses of estrogen receptor in endometrial adenocarcinoma using a monoclonal antibody. Cancer Res 46: 5419-5425, 1986. (Pubitemid 16008326)
22. Bland JM and Altman DG: Multiple significance tests: the Bonferroni method. BMJ 310: 170, 1995.
23. Cai KQ, Yang WL, Capo-Chichi CD, et al: Prominent expression of metalloproteinases in early stages of ovarian tumorigenesis. Mol Carcinogen 46: 130-143, 2007.
24. Shigemasa K, Tanimoto H, Sakata K, et al: Induction of matrix metalloprotease-7 is common in mucinous ovarian tumors including early stage disease. Med Oncol 17: 52-58, 2000. (Pubitemid 30159168)
25. Afzal S, Lalani EN, Poulsom R, et al: MT1-MMP and MMP-2 mRNA expression in human ovarian tumors: possible implications for the role of desmoplastic fibroblasts. Hum Pathol 29: 155-165, 1998. (Pubitemid 28099511)
26. Sakata K, Shigemasa K, Nagai N and Ohama K: Expression of matrix metalloproteinases (MMP-2, MMP-9, MT1-MMP) and their inhibitors (TIMP-1, TIMP-2) in common epithelial tumors of the ovary. Int J Oncol 17: 673-681, 2000.
27. Määttä M, Santala M, Soini Y, Talvensaari-Mattila A and Turpeenniemi-Hujanen T: Matrix metalloproteinases 2 and 9 and their tissue inhibitors in low malignant potential ovarian tumors. Tumor Biol 25: 188-192, 2004. (Pubitemid 39551745)
28. Behrens P, Rothe M, Florin A, Wellman A and Wernert N: Invasive properties of serous human epithelial ovarian tumors are related to Ets-1, MMP-1 and MMP-9 expression. Int J Mol Med 8: 149-154, 2001.
29. Ozalp S, Tanir HM, Yalcin OT, Kabukcuoglu S, Oner U and Uray M: Prognostic value of matrix metalloproteinase-9 (gelatinase B) expression in epithelial ovarian tumors. Eur J Gynaecol Oncol 24: 417-420, 2003. (Pubitemid 37236570)
30. Adley BP, Gleason KJ, Yang XJ and Stack MS: Expression of membrane type 1 matrix metalloproteinase (MMP-14) in epithelial ovarian cancer: high level expression in clear cell carcinoma. Gynecol Oncol 112: 319-324, 2009.
31. Demeter A, Sziller I, Csapo Z, et al: Molecular prognostic markers in recurrent and in non-recurrent epithelial ovarian cancer. Anticancer Res 25: 2885-2889, 2005.
32. Lengyel E, Schmalfeldt B, Konik E, et al: Expression of latent matrix metalloproteinase 9 (MMP-9) predicts survival in advanced ovarian cancer. Gynecol Oncol 82: 291-298, 2001. (Pubitemid 32730606)
33. Lin YG, Han LY, Kamat AA, et al: EphA2 overexpression is associated with angiogenesis in ovarian cancer. Cancer 109: 332-334, 2007.
34. Lin CK, Chao TK, Yu CP, Yu MH and Jin JS: The expression of six biomarkers in the four most common ovarian cancers: correlation with clinicopathological parameters. APMIS 117: 162-175, 2009.